Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • SWITCHMRK 032 and 033 studies evaluated virologically suppressed patients stable on lopinavir/ritonavir-based antiretroviral therapy with ≥ 2 NRTIs who were switched to raltegravir or continued their original regimen[Eron 2010]
    • Both studies were stopped prematurely because at Week 24 raltegravir failed to meet the protocol-defined criteria for noninferiority
  • SPIRAL study, which randomized patients suppressed on boosted-PI regimens to switch to raltegravir or continue their boosted PI, did not report an increased risk of virologic failure in the switch arm,[Martínez 2010] even in patients who had experienced previous virologic failure

Action required